A clinical research consortium sponsored by NIAID and JDRF
To identify and develop treatment “game changers” for tolerance modulating therapies for the treatment of immune mediated diseases and disabling onditions.
To conduct high quality, innovative clinical trials and mechanistic studies not likely to be funded by other sources or to be conducted by private industry that advance our understanding of immunological disorders.
In the ITN’s unique hybrid academic/industry model, the areas of academia, government and industry are integral to planning and conducting clinical studies. We develop and fund clinical trials and mechanistic studies in partnership.
Our development model is a unique, interactive process. It capitalizes on our wide-ranging, multidisciplinary expertise provided by an advisory board of highly respected faculty from institutions world-wide. This model gives investigators special insight into developing high quality research studies.
The ITN is comprised of leading scientific and medical faculty from more than 50 institutions in nine countries worldwide and employs over 80 full-time staff at the University of California San Francisco (UCSF), Bethesda, Maryland and Benaroya Research Institute in Seattle, Washington.
 | ITN Strategic Partnership Brochure
|
